OneArm2stage (Q86702): Difference between revisions

From MaRDI portal
Importer (talk | contribs)
Added link to MaRDI item.
 
(4 intermediate revisions by 2 users not shown)
description / endescription / en
Optimal One-Arm Two-Stage Phase II Design with Survival Endpoint
Phase II Single-Arm Two-Stage Designs with Time-to-Event Outcomes
Property / last update
1 December 2022
Timestamp+2022-12-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / last update: 1 December 2022 / rank
Normal rank
 
Property / software version identifier
 
1.1.4
Property / software version identifier: 1.1.4 / rank
 
Normal rank
Property / software version identifier: 1.1.4 / qualifier
 
publication date: 7 September 2022
Timestamp+2022-09-07T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / software version identifier
 
1.2.1
Property / software version identifier: 1.2.1 / rank
 
Normal rank
Property / software version identifier: 1.2.1 / qualifier
 
publication date: 9 October 2023
Timestamp+2023-10-09T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / last update
 
9 October 2023
Timestamp+2023-10-09T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / last update: 9 October 2023 / rank
 
Normal rank
Property / description
 
Two-stage design for single-arm phase II trials with time-to-event endpoints (e.g., clinical trials on immunotherapies among cancer patients) can be calculated using this package. Two notable advantages of the package: 1) It provides flexible choices from three design methods (optimal, minmax, and admissible), and 2) the power ofthe design is more accurately calculated using the exact variance in theone-sample log-rank test. The package can be used for 1) planning the samplesizes and other design parameters, and 2) conducting the interim and finalanalyses for the Go/No-go decisions. More details about the design methodcan be found in: Wu, J, Chen L, Wei J, Weiss H, Chauhan A. (2020).<doi:10.1002/pst.1983>.
Property / description: Two-stage design for single-arm phase II trials with time-to-event endpoints (e.g., clinical trials on immunotherapies among cancer patients) can be calculated using this package. Two notable advantages of the package: 1) It provides flexible choices from three design methods (optimal, minmax, and admissible), and 2) the power ofthe design is more accurately calculated using the exact variance in theone-sample log-rank test. The package can be used for 1) planning the samplesizes and other design parameters, and 2) conducting the interim and finalanalyses for the Go/No-go decisions. More details about the design methodcan be found in: Wu, J, Chen L, Wei J, Weiss H, Chauhan A. (2020).<doi:10.1002/pst.1983>. / rank
 
Normal rank
Property / author
 
Property / author: Xiaomeng Yuan / rank
 
Normal rank
Property / author
 
Property / author: Haitao Pan / rank
 
Normal rank
Property / author
 
Property / author: Jianrong Wu / rank
 
Normal rank
Property / copyright license
 
Property / copyright license: GNU General Public License / rank
 
Normal rank
Property / copyright license: GNU General Public License / qualifier
 
edition/version: ≥ 3 (English)
Property / imports
 
Property / imports: survival / rank
 
Normal rank
Property / imports
 
Property / imports: utils / rank
 
Normal rank
Property / imports
 
Property / imports: flexsurv / rank
 
Normal rank
Property / imports
 
Property / imports: IPDfromKM / rank
 
Normal rank
Property / cites work
 
Property / cites work: Two‐stage phase II survival trial design / rank
 
Normal rank
Property / depends on software
 
Property / depends on software: R / rank
 
Normal rank
Property / depends on software: R / qualifier
 
Property / MaRDI profile type
 
Property / MaRDI profile type: MaRDI software profile / rank
 
Normal rank
links / mardi / namelinks / mardi / name
 

Latest revision as of 19:56, 12 March 2024

Phase II Single-Arm Two-Stage Designs with Time-to-Event Outcomes
Language Label Description Also known as
English
OneArm2stage
Phase II Single-Arm Two-Stage Designs with Time-to-Event Outcomes

    Statements

    0 references
    1.1.5
    1 December 2022
    0 references
    1.1.4
    7 September 2022
    0 references
    1.2.1
    9 October 2023
    0 references
    0 references
    9 October 2023
    0 references
    Two-stage design for single-arm phase II trials with time-to-event endpoints (e.g., clinical trials on immunotherapies among cancer patients) can be calculated using this package. Two notable advantages of the package: 1) It provides flexible choices from three design methods (optimal, minmax, and admissible), and 2) the power ofthe design is more accurately calculated using the exact variance in theone-sample log-rank test. The package can be used for 1) planning the samplesizes and other design parameters, and 2) conducting the interim and finalanalyses for the Go/No-go decisions. More details about the design methodcan be found in: Wu, J, Chen L, Wei J, Weiss H, Chauhan A. (2020).<doi:10.1002/pst.1983>.
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references

    Identifiers

    0 references